에스토니아 - 에스토니아어 - Ravimiamet

sanofi winthrop industrie - levofloksatsiin - õhukese polümeerikattega tablett - 250mg 10tk; 250mg 1tk; 250mg 7tk; 250mg 5tk; 250mg 200tk; 250mg 3tk

에스토니아 - 에스토니아어 - Ravimiamet

winthrop arzneimittel gmbh - naatriumlevotüroksiin - tablett - 100mcg 100tk

에스토니아 - 에스토니아어 - Ravimiamet

sanofi winthrop industrie - amiodaroon - tablett - 200mg 30tk

에스토니아 - 에스토니아어 - Ravimiamet

sanofi winthrop industrie - valproehape - toimeainet prolongeeritult vabastav tablett - 500mg 30tk

에스토니아 - 에스토니아어 - Ravimiamet

sanofi winthrop industrie - valproehape - toimeainet prolongeeritult vabastav tablett - 300mg 100tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mitu müeloomit - antineoplastilised ained - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - leflunomiid - arthritis, rheumatoid; arthritis, psoriatic - immunosupressandid - leflunomiidi on näidustatud ravi täiskasvanud patsientidel:aktiivse reumatoidartriidi kui "haigust moduleeriva reumavastased uimasti" (dmard);aktiivse psoriaatilise artriidi. hiljutine või samaaegne ravi hepatotoxic või haematotoxic dmards e. metotreksaat) võib suurendada tõsiste kõrvaltoimete esinemise riski; seetõttu tuleb leflunomiidiravi alustamist nende kasu / riski aspektide osas hoolikalt kaaluda. lisaks sellele üleminek leflunomiidi teise dmard ilma pärast washout menetluse võib suureneda ka risk tõsiste kõrvaltoimete isegi pikka aega pärast lülitus.

에스토니아 - 에스토니아어 - Ravimiamet

sanofi winthrop industrie - naatriumenoksapariin - süstelahus süstlis - 2000rÜ 0.2ml 0.2ml 100tk; 2000rÜ 0.2ml 0.2ml 6tk; 2000rÜ 0.2ml 0.2ml 5tk; 2000rÜ 0.2ml 0.2ml 2tk; 2000rÜ 0.2ml 0.2ml 900tk; 2000rÜ 0.2ml 0.2ml 20tk; 2000rÜ 0.2ml 0.2ml 10tk; 2000rÜ 0.2ml 0.2ml 1000tk; 2000rÜ 0.2ml 0.2ml 30tk; 2000rÜ 0.2ml 0.2ml 2000tk